Parametrica Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Parametrica Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,232	Closed	-$418K	–	192
2022 Q2	$418K	Buy	5,232 +1,907	+57%	+$181K	0.46%	52
2022 Q1	$350K	Buy	+3,325	New	+$324K	0.26%	90
2021 Q2	–	Sell	-4,729	Closed	-$413K	–	204
2021 Q1	$413K	Buy	+4,729	New	+$399K	0.2%	85
2020 Q4	–	Sell	-3,620	Closed	-$281K	–	208
2020 Q3	$281K	Buy	+3,620	New	+$249K	0.53%	59
2019 Q2	–	Sell	-15,456	Closed	-$409K	–	158
2019 Q1	$409K	Buy	+15,456	New	+$366K	0.87%	23

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Parametrica Management's HZNP Position: Q3 2022 in Review

Parametrica Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 5,232 shares — an estimated $418K sold.

Parametrica Management first reported a position in HZNP in Q1 2019 and held it in 5 quarters. The position peaked at $418K in Q2 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Parametrica Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Parametrica Management sold 5,232 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $418K.
Parametrica Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 5 quarters.
Parametrica Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $418K in Q2 2022.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Parametrica Management's 13F filing for Q3 2022, filed 3 Nov 2022.